1.93
9.66%
+0.17
After Hours:
1.9799
0.0499
+2.59%
Fortress Biotech Inc stock is currently priced at $1.93, with a 24-hour trading volume of 334.28K.
It has seen a +9.66% increased in the last 24 hours and a +9.04% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.74 pivot point. If it approaches the $1.89 resistance level, significant changes may occur.
Previous Close:
$1.76
Open:
$1.75
24h Volume:
334.28K
Market Cap:
$93.64M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.13
EPS:
-14.85
Net Cash Flow:
$-129.56M
1W Performance:
+15.57%
1M Performance:
+9.04%
6M Performance:
-7.66%
1Y Performance:
+184.53%
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
2 Gansevoort Street, 9th Floor, New York, NY
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
Oct-02-20 | Initiated | The Benchmark Company | Buy |
Dec-18-19 | Initiated | B. Riley FBR | Buy |
Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech's (FBIO) Buy Rating Reaffirmed at Roth Mkm - Defense World
Defense World
Fortress Biotech (NASDAQ:FBIO) Raised to Hold at StockNews.com - Defense World
Defense World
Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase - GlobeNewswire
GlobeNewswire
Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase - Yahoo Finance Australia
Yahoo Finance Australia
Will Fortress Biotech to Surge Higher? - Yahoo Lifestyle UK
Yahoo Lifestyle UK
FBIO Stock Earnings: Fortress Biotech Beats EPS, Misses Revenue for Q1 2024 - MSN
MSN
Fortress Biotech Inc Stock (FBIO) Financials Data
Fortress Biotech Inc (FBIO) Revenue 2024
FBIO reported a revenue (TTM) of $80.97 million for the quarter ending September 30, 2023, a +4.32% rise year-over-year.
Fortress Biotech Inc (FBIO) Net Income 2024
FBIO net income (TTM) was -$78.31 million for the quarter ending September 30, 2023, a +14.13% increase year-over-year.
Fortress Biotech Inc (FBIO) Cash Flow 2024
FBIO recorded a free cash flow (TTM) of -$129.56 million for the quarter ending September 30, 2023, a +34.04% increase year-over-year.
Fortress Biotech Inc (FBIO) Earnings per Share 2024
FBIO earnings per share (TTM) was -$11.08 for the quarter ending September 30, 2023, a +32.46% growth year-over-year.
About Fortress Biotech Inc
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York..
Cap:
|
Volume (24h):